Compounds › Verified against primary sources

KLOW — the evidence

The blend still has no trial, but three components entered clinical phase in 2026

Not approvedVerified against primary sources

Experimental material. Read before using anything from here.

Nothing on this page is a medical recommendation, prescription or treatment plan. It is an organized translation of protocols circulating in research communities and, where it exists, of what published trials tested. The two are marked differently — and they are not equivalent.

Most of the compounds here have no FDA approval for human use. Several are sold labeled "research use only", which means they have not gone through purity, sterility or dosage controls for human consumption. A community-reported dose is not a validated dose: it is what someone reported having done.

Talk to a licensed health professional before considering any of these compounds. If you already use one and feel anything unexpected, seek care — do not wait for the next routine test.

Specific caution for this compound: The trials test the components in isolation and in different indications — hamstrings, cardiovascular disease and topical wound gel. The GHK-Cu trial is topical, not injectable: it does not validate the KLOW subcutaneous protocol.

Summary

Companion to the KLOW protocol page. No study has ever tested the four peptides together, and that has not changed. What changed is that BPC-157, TB-500 and GHK-Cu entered formal clinical trials for the first time: three Hudson Biotech studies, phase 1/2 and 2, started in February 2026 and are recruiting. It is no longer true to say the evidence for these compounds is only preclinical — but none of the trials tests the combination, and KPV still has nothing.

Why this page exists

The KLOW protocol page carries six tables of dose, titration and reconstitution, all from the commercial secondary source. This one answers a different question: what supports those numbers.

And the answer changed in 2026. The three main components of KLOW entered formal clinical trials for the first time — which makes it outdated to say, as was said until now, that the evidence is only preclinical.

The blend still has no trial

Before anything else, the point that has not changed: no study has ever tested the four peptides together. The ClinicalTrials.gov search for KLOW returns nothing, and there is no publication on the combination. Everything that exists is about each component in isolation.

This matters because the interaction between them is not known. GHK-Cu carries copper; KPV is anti-inflammatory; BPC-157 and TB-500 act on repair through different pathways. Adding four mechanisms in one vial is a bet by whoever assembles the blend, not a research finding.

What changed: the components entered trials

ClinicalTrials.gov survey on September 4, 2026. Three of these trials have the same sponsor, Hudson Biotech, and all started in February 2026 — it is a coordinated clinical development program, not scattered studies.

Component	Record	Phase	Condition	N	Sponsor	Status
BPC-157	NCT07437547	2	Grade II hamstring strain, MRI-confirmed	120	Hudson Biotech	Recruiting
BPC-157	NCT07803250	1	Recovery from rotator cuff repair	30	University of Arkansas	Not yet recruiting (Jan/2027)
BPC-157	NCT02637284	1	Healthy volunteers, safety and pharmacokinetics	42	PharmaCotherapia	Unknown status (2015)
TB-500	NCT07487363	1/2	Stable atherosclerotic cardiovascular disease, dose escalation	80	Hudson Biotech	Recruiting
GHK-Cu	NCT07437586	2	Topical gel for re-epithelialization of standardized wounds	60	Hudson Biotech	Recruiting
GHK-Cu	NCT07706361	N/A	GHK blood levels with the X39 patch	100	LifeWave	Not yet recruiting (2027)
KPV	—	—	No registered trial	—	—	—
KLOW (the blend)	—	—	No registered trial	—	—	—

The literature on each component

PubMed counts on the same date. Note the contrast between article volume and published clinical trials — it is the pattern of a compound heavily studied at the bench and little in people.

Component	Articles	Published clinical trials	Reading
BPC-157	271	2 (from 2002 and 2003)	Heavily studied in animal models, almost nothing in humans so far. The two published trials are more than twenty years old
GHK-Cu	180	3 (1992, 2006 and 2006)	It is the oldest of the four and the one with the most mature literature. But the three trials are topical — skin, wound and venous ulcer. None injectable
TB-500	26	9 (8 real)	One of the nine is a false positive: a tuberculosis study that matched the abbreviation TB. The eight real ones are all of full-length thymosin beta-4 — venous ulcer, dry eye, ischemic heart disease — not the seven-amino-acid fragment sold as TB-500
KPV	9 (in colitis)	2	Minimal base, concentrated in a colitis model. It is the component that sets KLOW apart from GLOW — and the one with the least backing

What this changes in practice

It is no longer true that the evidence is only preclinical. Three phase 1/2 and 2 trials are recruiting now. In 2027 there will be controlled human data where today there are community reports.
But none of them tests the blend. They test BPC-157 in hamstring injury, TB-500 in cardiovascular disease and GHK-Cu in topical gel — three different indications, by different routes, in isolation.
The GHK-Cu in the trial is topical, not injectable. The KLOW community protocol is subcutaneous. A wound-gel trial does not validate an injection.
KPV still has nothing. Precisely the component that justifies choosing KLOW over GLOW is the one with the least basis.
Worth following. The three Hudson Biotech trials have primary completion expected for February 2027. It is the first time these compounds will have a controlled outcome.

What this page does not answer

All four components now have closed counts, and closing them made the reading of KLOW worse, not better: the three GHK-Cu trials are topical and the eight TB-500 trials are of full-length thymosin beta-4. None of the eleven tested what the KLOW protocol says to inject. I did not read the full protocols of the recruiting trials: the doses they use were not in the summary record I consulted.

The KLOW dose tables remain on the protocol page, and they still come from the secondary source. No number there was validated by this survey.

References

This page did not come from the secondary source. Every number was collected by me from the sources listed below, on September 4, 2026, and the query used is stated above.

← Back to all compounds